Does the media prefer GALT or KURA?

In the previous week, Kura Oncology had 7 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for Kura Oncology and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Kura Oncology's score of 0.64 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ESPR or GALT?

In the previous week, Esperion Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Esperion Therapeutics and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Esperion Therapeutics' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, GALT or ANNX?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Annexon N/A N/A -$206.69M -$1.22 N/A

Is GALT or ANNX more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Annexon's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Annexon N/A -101.19% -75.99%

Does the media prefer GALT or ANNX?

In the previous week, Annexon had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Annexon and 1 mentions for Galectin Therapeutics. Annexon's average media sentiment score of 1.21 beat Galectin Therapeutics' score of 0.67 indicating that Annexon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annexon 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to DBVT or GALT?

In the previous week, DBV Technologies had 6 more articles in the media than Galectin Therapeutics. MarketBeat recorded 7 mentions for DBV Technologies and 1 mentions for Galectin Therapeutics. DBV Technologies' average media sentiment score of 1.05 beat Galectin Therapeutics' score of 0.67 indicating that DBV Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, GLAS or GALT?

Glass House Brands has higher revenue and earnings than Galectin Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.02M 4.60 N/A N/A N/A Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A

Is GLAS or GALT more profitable?

Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Galectin Therapeutics N/A N/A -164.69%

Galectin Therapeutics (GALT) Competitors

$3.03 +0.06 (+2.02%)

As of 08/3/2026 04:00 PM Eastern

Compare

GALT vs. KURA, ESPR, ANNX, DBVT, and GLAS

Should you buy Galectin Therapeutics stock or one of its competitors? MarketBeat compares Galectin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galectin Therapeutics include Kura Oncology (KURA), Esperion Therapeutics (ESPR), Annexon (ANNX), DBV Technologies (DBVT), and Glass House Brands (GLAS).

How does Galectin Therapeutics compare to Kura Oncology?

Galectin Therapeutics (NASDAQ:GALT) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 263.04%. Kura Oncology has a consensus target price of $25.46, suggesting a potential upside of 177.06%. Given Galectin Therapeutics' higher possible upside, research analysts plainly believe Galectin Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Galectin Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

In the previous week, Kura Oncology had 7 more articles in the media than Galectin Therapeutics. MarketBeat recorded 8 mentions for Kura Oncology and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Kura Oncology's score of 0.64 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Galectin Therapeutics has higher earnings, but lower revenue than Kura Oncology. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Kura Oncology	$67.48M	12.09	-$278.67M	-$3.35	N/A

Galectin Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Galectin Therapeutics' return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Kura Oncology	-411.19%	-141.95%	-43.28%

Summary

Galectin Therapeutics beats Kura Oncology on 8 of the 15 factors compared between the two stocks.

How does Galectin Therapeutics compare to Esperion Therapeutics?

Esperion Therapeutics (NASDAQ:ESPR) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Esperion Therapeutics currently has a consensus target price of $5.54, indicating a potential upside of 74.21%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 263.04%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, Esperion Therapeutics had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 2 mentions for Esperion Therapeutics and 1 mentions for Galectin Therapeutics. Galectin Therapeutics' average media sentiment score of 0.67 beat Esperion Therapeutics' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Esperion Therapeutics has higher revenue and earnings than Galectin Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$403.14M	2.03	-$22.68M	-$0.06	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

Esperion Therapeutics has a net margin of 0.12% compared to Galectin Therapeutics' net margin of 0.00%. Galectin Therapeutics' return on equity of 0.00% beat Esperion Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	0.12%	-0.14%	0.12%
Galectin Therapeutics	N/A	N/A	-164.69%

Esperion Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market.

47.4% of Esperion Therapeutics shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 1.6% of Esperion Therapeutics shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Esperion Therapeutics beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Annexon?

Galectin Therapeutics (NASDAQ:GALT) and Annexon (NASDAQ:ANNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Galectin Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the broader market. Comparatively, Annexon has a beta of 1.18, suggesting that its share price is 18% more volatile than the broader market.

In the previous week, Annexon had 4 more articles in the media than Galectin Therapeutics. MarketBeat recorded 5 mentions for Annexon and 1 mentions for Galectin Therapeutics. Annexon's average media sentiment score of 1.21 beat Galectin Therapeutics' score of 0.67 indicating that Annexon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Annexon	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Annexon	N/A	N/A	-$206.69M	-$1.22	N/A

Galectin Therapeutics' return on equity of 0.00% beat Annexon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Annexon	N/A	-101.19%	-75.99%

Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 263.04%. Annexon has a consensus target price of $15.33, suggesting a potential upside of 192.06%. Given Galectin Therapeutics' higher probable upside, equities analysts clearly believe Galectin Therapeutics is more favorable than Annexon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Annexon	3 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.20

11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 10.3% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Annexon beats Galectin Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Galectin Therapeutics compare to DBV Technologies?

DBV Technologies (NASDAQ:DBVT) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Galectin Therapeutics has lower revenue, but higher earnings than DBV Technologies. Galectin Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DBV Technologies	$5.64M	142.59	-$146.95M	-$3.51	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

71.7% of DBV Technologies shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 1.1% of DBV Technologies shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, DBV Technologies had 6 more articles in the media than Galectin Therapeutics. MarketBeat recorded 7 mentions for DBV Technologies and 1 mentions for Galectin Therapeutics. DBV Technologies' average media sentiment score of 1.05 beat Galectin Therapeutics' score of 0.67 indicating that DBV Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DBV Technologies	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

DBV Technologies presently has a consensus price target of $48.50, suggesting a potential upside of 257.14%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 263.04%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than DBV Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Galectin Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Galectin Therapeutics' return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DBV Technologies	-3,506.53%	-119.33%	-84.43%
Galectin Therapeutics	N/A	N/A	-164.69%

DBV Technologies has a beta of -0.93, indicating that its stock price is 193% less volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

Summary

DBV Technologies beats Galectin Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Galectin Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-164.69%

Glass House Brands presently has a consensus price target of $17.00, suggesting a potential upside of 68.42%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 263.04%. Given Galectin Therapeutics' higher probable upside, analysts clearly believe Galectin Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Galectin Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Glass House Brands has higher revenue and earnings than Galectin Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.02M	4.60	N/A	N/A	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

In the previous week, Galectin Therapeutics had 1 more articles in the media than Glass House Brands. MarketBeat recorded 1 mentions for Galectin Therapeutics and 0 mentions for Glass House Brands. Galectin Therapeutics' average media sentiment score of 0.67 beat Glass House Brands' score of 0.00 indicating that Galectin Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Glass House Brands	Neutral
Galectin Therapeutics	Positive

11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Galectin Therapeutics beats Glass House Brands on 5 of the 9 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$195.60M	$3.55B	$6.86B	$12.44B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-7.39	7.29	280.74	24.99
Price / Sales	N/A	1,264.35	588.16	90.43
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	-1.52	16.89	11.02	6.21
Net Income	-$30.84M	-$12.54M	$3.48B	$347.49M
7 Day Performance	-10.62%	0.31%	0.81%	1.29%
1 Month Performance	-32.82%	-7.40%	-4.15%	-3.59%
1 Year Performance	-15.60%	47.13%	61.47%	18.38%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	2.3635 of 5 stars	$3.03 +2.0%	$11.00 +263.0%	-17.0%	$195.60M	N/A	N/A	9
KURA Kura Oncology	3.5163 of 5 stars	$9.38 -7.6%	$25.46 +171.4%	+52.7%	$838.61M	$67.48M	N/A	130	Upcoming Earnings
ESPR Esperion Therapeutics	1.5987 of 5 stars	$3.18 flat	$5.54 +74.2%	N/A	$819.45M	$403.14M	N/A	200
ANNX Annexon	3.9879 of 5 stars	$4.97 -3.2%	$15.33 +208.8%	+114.3%	$810.20M	N/A	N/A	60
DBVT DBV Technologies	3.2835 of 5 stars	$13.38 -3.7%	$48.50 +262.5%	+50.9%	$788.09M	$5.64M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. KURA, ESPR, ANNX, DBVT, and GLAS

How does Galectin Therapeutics compare to Kura Oncology?

Summary

How does Galectin Therapeutics compare to Esperion Therapeutics?

Summary

How does Galectin Therapeutics compare to Annexon?

Summary

How does Galectin Therapeutics compare to DBV Technologies?

Summary

How does Galectin Therapeutics compare to Glass House Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. KURA, ESPR, ANNX, DBVT, and GLAS

How does Galectin Therapeutics compare to Kura Oncology?

Do analysts prefer GALT or KURA?

Which has more risk & volatility, GALT or KURA?

Does the media prefer GALT or KURA?

Do insiders and institutionals have more ownership in GALT or KURA?

Which has better earnings & valuation, GALT or KURA?

Is GALT or KURA more profitable?

Summary

How does Galectin Therapeutics compare to Esperion Therapeutics?

Do analysts prefer ESPR or GALT?

Does the media refer more to ESPR or GALT?

Which has better valuation & earnings, ESPR or GALT?

Is ESPR or GALT more profitable?

Which has more risk and volatility, ESPR or GALT?

Do insiders & institutionals believe in ESPR or GALT?

Summary

How does Galectin Therapeutics compare to Annexon?

Which has more volatility and risk, GALT or ANNX?

Does the media prefer GALT or ANNX?

Which has stronger earnings & valuation, GALT or ANNX?

Is GALT or ANNX more profitable?

Do analysts recommend GALT or ANNX?

Do institutionals & insiders hold more shares of GALT or ANNX?

Summary

How does Galectin Therapeutics compare to DBV Technologies?

Which has stronger earnings & valuation, DBVT or GALT?

Do institutionals and insiders hold more shares of DBVT or GALT?

Does the media refer more to DBVT or GALT?

Do analysts recommend DBVT or GALT?

Is DBVT or GALT more profitable?

Which has more volatility & risk, DBVT or GALT?

Summary

How does Galectin Therapeutics compare to Glass House Brands?

Is GLAS or GALT more profitable?

Do analysts rate GLAS or GALT?

Which has stronger valuation and earnings, GLAS or GALT?

Does the media refer more to GLAS or GALT?

Do institutionals & insiders have more ownership in GLAS or GALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools